Neurogene received FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome, driving a >25% share price surge. Click ...

HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT ...

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...

AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) ...

Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program -- First-in-kind technology ...

Applications are now open for the 2026 EANM Young Scientist Network Award. This new research award, supported by Advanced ...

Kids these days...they talk about their feelings and consider therapy a normal part of healthcare. It's (mostly) all good news.

Atara Biotherapeutics (ATRA) stock jumps as an FDA top official reportedly overruled internal reviewers in rejecting the company's cell therapy. Read more here.

The Radioligand Therapy Market is projected to reach US$13 billion by 2030, growing at an estimated rate of 5%. Key drivers of this growth include the rising incidence of cancers such as prostate ...

Germany’s Bayer has announced encouraging results from the ongoing global Phase I first-in-human dose-escalation PAnTHa study of 225Ac-PSMA-Trillium, a targeted alpha therapy in advanced metastatic ca ...

In a retrospective review, the combination of tumor necrosis factor-alpha (TNF‑alpha) inhibitors with immunomodulators was associated with an increased risk for skin and soft tissue infections in ...